It can be concluded that primary NSCLC cells are able to downregulate the expression of CD40, CD80, CD86, and HLA-DR on CD1c+ DCs after incubation with DCs derived from the same NSCLC patients. The gene discussed is CD80; the disease is non-small cell lung carcinoma.